Herold, Z.; Acs, M.; Szasz, A.M.; Olasz, K.; Hussong, J.; Mayr, M.; Dank, M.; Piso, P.
Patients with Metachronous Peritoneal Metastatic Mucinous Colorectal Adenocarcinoma Benefit More from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) than Their Synchronous Counterparts. Cancers 2022, 14, 3978.
https://doi.org/10.3390/cancers14163978
AMA Style
Herold Z, Acs M, Szasz AM, Olasz K, Hussong J, Mayr M, Dank M, Piso P.
Patients with Metachronous Peritoneal Metastatic Mucinous Colorectal Adenocarcinoma Benefit More from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) than Their Synchronous Counterparts. Cancers. 2022; 14(16):3978.
https://doi.org/10.3390/cancers14163978
Chicago/Turabian Style
Herold, Zoltan, Miklos Acs, Attila Marcell Szasz, Katalin Olasz, Jana Hussong, Max Mayr, Magdolna Dank, and Pompiliu Piso.
2022. "Patients with Metachronous Peritoneal Metastatic Mucinous Colorectal Adenocarcinoma Benefit More from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) than Their Synchronous Counterparts" Cancers 14, no. 16: 3978.
https://doi.org/10.3390/cancers14163978
APA Style
Herold, Z., Acs, M., Szasz, A. M., Olasz, K., Hussong, J., Mayr, M., Dank, M., & Piso, P.
(2022). Patients with Metachronous Peritoneal Metastatic Mucinous Colorectal Adenocarcinoma Benefit More from Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) than Their Synchronous Counterparts. Cancers, 14(16), 3978.
https://doi.org/10.3390/cancers14163978
